ERBB2 and breast carcinoma: Finally, whole genome sequencing analysis of luminal cells isolated 6 weeks after sEVHYP injection in vivo showed no significant increase in the number of mutations (Supplemental Figure 9A), including coding mutations (Supplemental Figure 9B) or alterations in key breast cancer genes, such as TP53, PIK3CA, MYC, PTEN, CCND1, ERBB2, FGFRI, or GATA3, in comparison with controls.